102 articles tagged with #drug-discovery. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Researchers have developed an exascale workflow using graph foundation models trained on 544+ million atomistic structures to accelerate materials discovery. The system can screen 1.1 billion structures in 50 seconds—a task requiring years of traditional computation—and demonstrates strong transfer learning capabilities across diverse chemical applications.
OpenAI has launched GPT-Rosalind, an AI model designed to accelerate pharmaceutical drug discovery, partnering with major life sciences companies including Amgen, Moderna, and Thermo Fisher. The model represents a significant application of advanced AI technology beyond traditional software domains, with potential to compress drug development timelines and reduce research costs.
Metanova Labs is revolutionizing drug discovery by using Bittensor's decentralized AI network to screen billions of molecules efficiently. The platform utilizes combinatorial reactions to expand screening possibilities to 65 billion compounds and implements dual incentive mechanisms to drive innovation in pharmaceutical research.
Researchers introduce Logos, a compact AI model that combines multi-step logical reasoning with chemical consistency for molecular design. The model achieves strong performance in structural accuracy and chemical validity while using fewer parameters than larger language models, and provides transparent reasoning that can be inspected by humans.
Researchers have introduced Mozi, a dual-layer architecture designed to make AI agents more reliable for drug discovery by implementing governance controls and structured workflows. The system addresses critical issues of unconstrained tool use and poor long-term reliability that have limited LLM deployment in pharmaceutical research.
Researchers introduce MMAI Gym for Science, a training framework for molecular foundation models in drug discovery. Their Liquid Foundation Model (LFM) outperforms larger general-purpose models on drug discovery tasks while being more efficient and specialized for molecular applications.
Researchers developed a new AI-powered framework for crystal structure prediction that uses large language models and symmetry-driven generation to overcome computational bottlenecks. The approach achieves state-of-the-art performance in discovering new materials without relying on existing databases, potentially accelerating materials science research.
Researchers developed RxnNano, a compact 0.5B-parameter AI model for chemical reaction prediction that outperforms much larger 7B+ parameter models by 23.5% through novel training techniques focused on chemical understanding rather than scale. The framework uses hierarchical curriculum learning and chemical consistency objectives to improve drug discovery and synthesis planning applications.
Researchers developed a Neuro-Symbolic Agentic Framework combining machine learning with LLM-based reasoning to predict colorectal cancer drug responses. The system achieved significant predictive accuracy (r=0.504) and introduces 'Inverse Reasoning' for simulating genomic edits to predict drug sensitivity changes.
Researchers have developed FROGENT, an AI multi-agent system that uses large language models to automate the entire drug discovery pipeline from target identification to synthesis planning. The system outperformed existing AI approaches across eight benchmarks and demonstrated practical applications in real-world drug design scenarios.
Researchers developed mCLM, a 3-billion parameter modular Chemical Language Model that generates functional molecules compatible with automated synthesis by tokenizing at the building block level rather than individual atoms. The AI system outperformed larger models including GPT-5 in creating synthesizable drug candidates and can iteratively improve failed clinical trial compounds.
AlphaFold has significantly accelerated scientific research and biological discovery over the past five years. The AI system has enabled breakthroughs in protein structure prediction, fueling innovation across the global scientific community.
Google has launched a new 27 billion parameter foundation model for single-cell analysis, built on the Gemma family of open models. The model has reportedly helped discover a new potential cancer therapy pathway, demonstrating practical medical applications of AI technology.
Demis Hassabis and John Jumper have been awarded the Nobel Prize in Chemistry for developing AlphaFold, an AI system that predicts 3D protein structures from amino acid sequences. This recognition highlights the transformative impact of AI in scientific research and drug discovery.
Researchers introduce BALD-GFlowNet, a generative active learning framework that replaces traditional pool-based sample selection with generative sampling to dramatically improve scalability. The method maintains comparable performance to standard BALD while reducing computational costs independent of unlabeled dataset size, particularly valuable for drug discovery applications involving billions of molecular candidates.
Researchers propose uncertainty-aware reinforcement learning methods for chemical language models that account for prediction confidence when optimizing molecular properties. By incorporating predictive uncertainty into the optimization process, the approach improves hit discovery rates from 50% to 75% while maintaining molecular quality scores.
Stripe, Anthropic, and OpenAI are jointly backing a new initiative to develop treatments and prevention methods for respiratory infections like the common cold. The effort represents a convergence of major tech and AI companies into the biotech and healthcare space, potentially leveraging artificial intelligence for drug discovery and medical research.
Nvidia has launched the BioNeMo Agent Toolkit, an AI framework designed to accelerate drug discovery and biological research by automating complex research workflows. While the toolkit promises significant efficiency gains in the pharmaceutical and biotech sectors, questions about reliability and real-world validation remain open.
Researchers introduce ACTIVA, a transformer-based variational autoencoder designed to estimate causal interventional distributions from observational data without requiring intervention datasets. The model amortizes causal knowledge across tasks, enabling zero-shot inference and outperforming existing baselines on synthetic and biological datasets while reducing spurious correlations.
Researchers developed an explainable graph neural network framework that uses group lasso regularization to predict compound-protein affinity and identify critical molecular substructures in drug discovery. The approach leverages activity-cliff molecule pairs to improve predictions for tyrosine-protein kinases and other targets, demonstrating enhanced interpretability and accuracy in molecular property prediction.
Researchers propose a training-free caching strategy that accelerates molecular geometry generation in flow matching models by predicting intermediate hidden states, achieving 2-7x speedups without quality degradation. The method is compatible with pretrained models and compounds with existing optimizations, addressing a critical inference bottleneck in computational chemistry workflows.
Researchers introduce MMGNN (Multi-level, Multi-color Graph Neural Networks), a novel neural network architecture that decomposes molecular graphs into interaction-specific subgraphs to improve molecular property prediction. The framework demonstrates competitive performance across multiple benchmarks, with variants optimized for topological and geometric molecular representations.
Researchers introduce Chem2Gen-Bench, a comprehensive benchmark dataset containing over 1.3 million chemical and genetic perturbation profiles designed to evaluate how accurately computational models can translate chemical perturbations into genetic responses. The study reveals that while translation between these perturbation types is measurable, it remains heterogeneous across different cellular contexts, and current foundation-model embeddings don't consistently outperform simpler baseline approaches.
Researchers used sparse autoencoders to mechanistically analyze MolFormer, a chemical language model, revealing that it learns meaningful molecular semantics beyond surface-level syntax. Early layers track molecular grammar through position-encoding, while deeper layers capture pharmacologically relevant atomic features, with non-canonical SMILES notations causing more disruption than invalid ones due to cascading positional errors.
Researchers introduced TxBench-PP, a benchmark testing AI agents' ability to analyze real-world drug discovery data rather than regurgitate memorized information. Testing 11 AI models across 4,800 trajectories revealed significant limitations: even the best-performing system (Claude Opus) succeeded only 59% of the time on preclinical pharmacology tasks, suggesting AI agents require substantial improvement before reliable deployment in drug discovery workflows.
